Fulcrum Therapeutics, Inc. logo FULC - Fulcrum Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 11
HOLD 4
SELL 1
STRONG
SELL
0
| PRICE TARGET: $20.67 DETAILS
HIGH: $25.00
LOW: $10.00
MEDIAN: $23.50
CONSENSUS: $20.67
UPSIDE: 214.61%
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017
Revenue
Revenue 0 80 2.8 6.3 19.2 8.8 0 0 0
Cost of Revenue 1.4 63.4 0 76.8 69.7 59.0 2.1 1.3 0.7
Gross Profit (1.4) 16.6 2.8 (70.4) (50.5) (50.2) (2.1) (1.3) (0.7)
Operating Expenses
R&D Expenses 56.1 63.4 71.8 76.8 69.7 59.0 43.4 25.2 18.5
SG&A Expenses 28.7 36.4 41.7 41.7 30.5 21.4 13.1 8.3 4.5
Other Expenses (1.4) (61.3) 0 (76.4) (69.7) (59.0) 0 0.4 0.0
Operating Expenses 83.4 38.5 113.5 42.1 30.5 21.4 56.6 33.5 23.0
Operating Income
Operating Income (84.8) (21.9) (110.7) (112.6) (81.1) (71.6) (58.6) (33.5) (23.0)
Interest Expense 0 0 0 0 0 0 0 0 0
Interest Income 0 0 0 0 0.2 0.8 1.5 0 0
Profitability
EBITDA (73.5) (18.2) (108.5) (109.7) (78.5) (69.2) (80.6) (32.2) (22.3)
EBIT (74.9) (19.8) (110.7) (112.1) (81.1) (71.6) (82.7) (33.5) (23.0)
Income Before Tax (74.9) (9.7) (97.3) (109.9) (80.8) (70.8) (82.7) (32.6) (23.0)
Income Tax Expense 0 0 0 0 0 0 0 0 (0.0)
Net Income (74.9) (9.7) (97.3) (109.9) (80.8) (70.8) (82.7) (32.6) (23.0)
Per Share Data
EPS (Basic) -1.18 -0.16 -1.59 -2.35 -2.22 -2.70 -3.49 -1.92 -1.36
EPS (Diluted) -1.18 -0.16 -1.59 -2.35 -2.22 -2.70 -3.49 -1.92 -1.36
Shares Outstanding 63.4 62.0 61.3 45.0 35.4 25.4 22.7 16.9 16.9
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017
Current Assets
Cash & Cash Equivalents 197.5 58.2 25.6 35.1 35.4 57.1 96.7 72.8 0.4
Short-Term Investments 154.8 182.8 210.7 167.8 182.8 55.9 0 0 0
Net Receivables 1.1 3.3 2.2 1.1 4.1 2.7 0.1 0.5 0.0
Inventory 0 0 0 0 (0.5) (2.8) 3.0 0.6 0.7
Other Current Assets 5.2 0 0 0 0 0.1 0.3 0.2 0.2
Total Current Assets 357.5 249.9 242.2 207.5 226.0 112.9 100.1 74.1 1.3
Non-Current Assets
Property, Plant & Equipment 7.1 9.6 12.4 16.0 7.4 8.4 87.9 10.5 2.9
Goodwill 0 0 0 0 0 0 0 0 0
Intangible Assets 0 0 0 0 0 0 0 0 0
Long-Term Investments 0 0 0 1.1 1.1 1.1 1.1 1.1 0
Other Non-Current Assets 1.7 1.2 3.1 2.1 0.5 7.2 (78.7) 0.0 0.1
Total Non-Current Assets 8.8 10.8 15.5 19.2 9.0 16.7 10.4 11.7 3.0
Total Assets 366.3 260.7 257.7 226.7 235 129.6 110.4 85.8 4.3
Current Liabilities
Account Payables 1.6 1.2 2.8 3.6 4.8 4.1 2.2 1.3 1.7
Short-Term Debt 2.4 0 0 2.6 0 0 0 0 0
Deferred Revenue 0 0 0 0.9 4.7 14.9 4.0 2.8 0
Other Current Liabilities 9.1 0.5 0.4 5.3 4.7 4.8 3.7 0.8 0.0
Total Current Liabilities 13.0 11.0 13.7 16.7 19.2 26.7 12.1 4.2 2.8
Non-Current Liabilities
Long-Term Debt 4.0 0 0 0 0 0 0 0 34.6
Deferred Tax Liabilities 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 0.2 0.2 0.2 0 4.3 4.7 5.1 5.5 (34.4)
Total Non-Current Liabilities 4.2 6.6 8.8 11.0 4.3 7.7 11.1 5.5 0.2
Total Liabilities 17.3 17.7 22.5 27.7 23.5 34.4 23.3 9.8 3.0
Stockholders' Equity
Common Stock 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0
Retained Earnings (594.3) (519.4) (509.7) (412.3) (302.5) (221.6) (150.8) (68.1) (35.5)
Accumulated Other Comprehensive Income 0 0.1 (0.1) (0.8) (0.4) (0.0) (110.4) (2.0) (0.9)
Total Stockholders' Equity 349 243.0 235.2 198.9 211.5 95.2 87.2 76 1.3
Total Liabilities & Equity 366.3 260.7 257.7 226.7 235 129.6 110.4 85.8 4.3
Debt Metrics
Total Debt 6.4 8.6 10.8 13.4 0 0.0 0.1 0.0 34.6
Net Debt (191.1) (49.6) (14.7) (21.7) (35.4) (57.0) (96.7) (72.8) 34.2
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017
Operating Activities
Net Income (74.9) (9.7) (97.3) (109.9) (80.8) (70.8) (82.7) (32.6) (23.0)
Depreciation & Amortization 1.4 1.6 2.2 2.4 2.5 2.4 2.1 1.3 0.7
Stock-Based Compensation 12.5 14.6 14.8 13.3 11.1 7.3 4.2 2.2 1.4
Change in Working Capital 3.9 (4.2) (4.6) (3.1) (11.9) 7.5 11.3 6.5 0.8
Other Non-Cash Items (3.0) (4.4) (6.0) 0.2 0.7 (2) 25.6 4.9 2.6
Operating Cash Flow (60.1) (2.2) (91.0) (97.0) (78.5) (53.7) (39.5) (22.6) (20.1)
Investing Activities
Capital Expenditure (0.3) (0.3) (0.5) (2.0) (1.7) (1.3) (0.9) (9.0) (1.9)
Acquisitions 0 0 0 (14.4) 128.0 55.8 0 0 0
Purchases of Investments (180.2) (178.6) (194.9) (151.2) (216.2) (124.3) 0 0 0
Sales/Maturities of Investments 211.3 211.1 158.7 165.5 88.3 68.5 0 0 0
Other Investing Activities 0 0 0 14.4 (128.0) (55.8) (0.1) 0 0
Investing Cash Flow 30.7 32.2 (36.7) 12.4 (129.7) (57.1) (0.9) (9.0) (1.9)
Financing Activities
Net Debt Issuance 0 0 0 0 (0.0) (0.1) (0.0) (0.1) 0
Stock Repurchased 0 0 0 0 0 0 0 0 0
Dividends Paid 0 0 0 0 0 0 0 0 0
Other Financing Activities 0 0 0.8 3.5 3.7 1.2 0.2 0.0 17.7
Financing Cash Flow 168.7 2.7 118.1 84.3 186.5 71.1 64.3 105.0 17.7
Cash Position
Net Change in Cash 139.3 32.8 (9.5) (0.3) (21.6) (39.7) 23.9 73.5 (4.3)
Cash at Beginning 59.4 26.7 36.2 36.5 58.1 97.8 73.9 0.4 4.7
Cash at End 198.7 59.4 26.7 36.2 36.5 58.1 97.8 73.9 0.4
Free Cash Flow (60.4) (2.5) (91.5) (99.0) (80.2) (55.0) (40.3) (31.5) (22.0)
Key Metrics 2025 2024 2023 2022 2021 2020 2019 2018 2017
Income Statement
Revenue 0 80 2.8 6.3 19.2 8.8 0 0 0
Gross Profit (1.4) 16.6 2.8 (70.4) (50.5) (50.2) (2.1) (1.3) (0.7)
Operating Income (84.8) (21.9) (110.7) (112.6) (81.1) (71.6) (58.6) (33.5) (23.0)
Net Income (74.9) (9.7) (97.3) (109.9) (80.8) (70.8) (82.7) (32.6) (23.0)
EPS (Diluted) -1.18 -0.16 -1.59 -2.35 -2.22 -2.70 -3.49 -1.92 -1.36
Balance Sheet
Cash & Equivalents 197.5 58.2 25.6 35.1 35.4 57.1 96.7 72.8 0.4
Total Assets 366.3 260.7 257.7 226.7 235 129.6 110.4 85.8 4.3
Total Debt 6.4 8.6 10.8 13.4 0 0.0 0.1 0.0 34.6
Stockholders' Equity 349 243.0 235.2 198.9 211.5 95.2 87.2 76 1.3
Cash Flow
Operating Cash Flow (60.1) (2.2) (91.0) (97.0) (78.5) (53.7) (39.5) (22.6) (20.1)
Capital Expenditure (0.3) (0.3) (0.5) (2.0) (1.7) (1.3) (0.9) (9.0) (1.9)
Free Cash Flow (60.4) (2.5) (91.5) (99.0) (80.2) (55.0) (40.3) (31.5) (22.0)